Ultragenyx Pharmaceutical (RARE) Set to Announce Earnings on Wednesday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is scheduled to issue its quarterly earnings data on Wednesday, April 17th.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.13. The business had revenue of $127.39 million during the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. Ultragenyx Pharmaceutical’s revenue was up 23.3% compared to the same quarter last year. During the same period last year, the business earned ($2.16) EPS. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $42.87 on Tuesday. The firm has a 50-day simple moving average of $48.22 and a two-hundred day simple moving average of $43.39. Ultragenyx Pharmaceutical has a fifty-two week low of $31.52 and a fifty-two week high of $54.98. The firm has a market cap of $3.53 billion, a P/E ratio of -5.15 and a beta of 0.65.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 4,173 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the transaction, the insider now owns 89,268 shares of the company’s stock, valued at $4,799,047.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Karah Herdman Parschauer sold 3,756 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $201,922.56. Following the sale, the executive vice president now owns 67,340 shares in the company, valued at $3,620,198.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John Richard Pinion sold 4,173 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the completion of the sale, the insider now owns 89,268 shares in the company, valued at approximately $4,799,047.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,974 shares of company stock valued at $1,639,721. 6.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Ultragenyx Pharmaceutical by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock valued at $414,764,000 after acquiring an additional 1,440,264 shares during the last quarter. BlackRock Inc. increased its position in Ultragenyx Pharmaceutical by 4.0% during the second quarter. BlackRock Inc. now owns 5,067,027 shares of the biopharmaceutical company’s stock valued at $233,742,000 after acquiring an additional 193,671 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Ultragenyx Pharmaceutical by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,448,698 shares of the biopharmaceutical company’s stock valued at $164,918,000 after acquiring an additional 288,538 shares during the last quarter. Wellington Management Group LLP increased its position in Ultragenyx Pharmaceutical by 17.1% during the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock valued at $244,747,000 after acquiring an additional 492,842 shares during the last quarter. Finally, Clearbridge Investments LLC increased its position in Ultragenyx Pharmaceutical by 3.1% during the first quarter. Clearbridge Investments LLC now owns 2,863,921 shares of the biopharmaceutical company’s stock valued at $207,978,000 after acquiring an additional 85,062 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RARE. Wedbush lifted their price target on shares of Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, February 16th. Robert W. Baird raised their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. JPMorgan Chase & Co. raised their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, April 5th. Finally, Canaccord Genuity Group raised their price objective on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $91.55.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.